Balazs Halmos, MD

Articles

Dr Halmos on Novel Targets for Drug Development in SCLC

December 16th 2024

Balazs Halmos, MD, discusses novel targets for drug development in small cell lung cancer.

Dr Halmos on the Challenges of Diagnosing SCLC

December 16th 2024

Balazs Halmos, MD, discusses challenges associated with the diagnosis and treatment of patients with small cell lung cancer.

Leveraging ctDNA Platforms in High-Risk Patients: Current Applications and Future Potential

December 6th 2024

Panelists discuss how they currently utilize emerging ctDNA platforms for high-risk patients and explore whether these advancements will soon become standard practice in clinical decision-making.

Translating Metastatic Insights to Early-Stage Management: Current Practices and Future Direction

November 29th 2024

Panelists discuss how the field aims to translate lessons learned from metastatic treatment into earlier-stage interventions for select patients, sharing their current practices and hopes for future advancements in care.

EGFR Therapy Evolution: Resistance Mechanisms, Combination Strategies, and Advanced Testing

November 29th 2024

Panelists discuss how recent insights into delayed resistance mechanisms in EGFR-positive cancers, including the role of combination therapies and improved testing methods, are shaping strategies to better manage and overcome resistance.

Future Directions in ALK-Positive and BRAF-Positive NSCLC Management

November 22nd 2024

Panelists discuss how advancements in targeted therapies and personalized medicine are crucial for addressing the pressing unanswered questions in the management of ALK-positive and BRAF-positive cancers.

Precision BRAF Therapy: Optimizing Dosing, Sequencing, and Toxicity Management in NSCLC

November 22nd 2024

Panelists discuss the role of immunotherapy in the treatment landscape for BRAF-positive NSCLC, considering factors influencing the choice between immunotherapy and targeted therapy, emerging therapies, ongoing clinical trials, and approaches to dosing, sequencing, and toxicity management for both ALK and BRAF inhibitors.

Long-Term Outcomes of BRAF-MEK Inhibitor Combinations

November 15th 2024

Panelists discuss recent data on progression-free survival (PFS) and duration of response (DOR) for BRAF-MEK inhibitor combinations, including encorafenib + binimetinib and dabrafenib + trametinib, while also addressing emerging safety signals, differences in response based on treatment lines, and considerations for dose modifications and sequencing strategies in clinical practice.

Combination Therapies in BRAF-Positive NSCLC

November 15th 2024

Panelists discuss their insights on current and emerging combination strategies in the treatment of BRAF-positive NSCLC, focusing on the integration of targeted therapies, immunotherapies, or both.

From Early Stage to Resistance: ALINA Study Insights and ALK Inhibitor Sequencing Strategies

November 8th 2024

Panelists discuss the findings from the ALINA study on adjuvant alectinib vs chemotherapy in resected ALK-positive NSCLC, considering how these results may influence early-stage management, sequencing strategies for ALK inhibitors, and the role of resistance mechanisms in treatment decisions.

Intracranial Efficacy of Next-Generation ALK-Targeted Therapies

November 8th 2024

Panelists discuss the efficacy of ALK inhibitors in treating brain metastases, referencing data from the REMARK study, the CROWN trial, ALTA-3, and ALTA-1L/brigatinib, among others.

Optimizing ALK-TKI Sequencing and Neurological Outcomes

November 1st 2024

Panelists discuss the circumstances under which they would consider switching patients on different first-line treatments to lorlatinib and outline approaches for CNS surveillance and management in ALK-positive patients.

Clinical Impact of ALK Inhibitor Data: Efficacy, Brain Metastases, and CNS Management Strategies

November 1st 2024

Panelists discuss how recent data influence treatment choices for ALK-positive NSCLC patients, highlighting specific patient factors that guide decisions and potential concerns regarding the use of lorlatinib as first-line therapy.

CROWN and BRIGHTSTAR Studies: Latest Data Insights

October 25th 2024

Panelists discuss the key findings from the latest data from the CROWN and BRIGHTSTAR studies, emphasizing efficacy end points and comparing the effectiveness of these regimens with that of others in the treatment landscape for ALK-positive NSCLC.

Molecular Testing and First-Line Treatment Selection in ALK-Positive NSCLC

October 25th 2024

Panelists discuss the importance of molecular testing in NSCLC, particularly for ALK rearrangements, and explore how recent advancements and emerging technologies are shaping first-line treatment selection for ALK-positive patients.

Halmos on the AE Profiles of Dato-DXd and Other ADCs in NSCLC

August 5th 2024

Dr Halmos discusses common AEs associated with the ADCs that are used in NSCLC and ways to manage and mitigate these toxicities.

Dr Halmos on Treatment Strategies For EGFR-Mutant NSCLC

February 4th 2024

Balazs Halmos, MD, discusses treatment strategies for patients with EGFR-mutant non–small cell lung cancer.

What is the Role of Molecular Testing in Resectable Non–Small Cell Lung Cancer?

May 5th 2023

Shared insight from key opinion leaders on the value of molecular testing in patients with resectable non–small cell lung cancer and how it can be applied.

Dr. Halmos on the Safety and Efficacy of Lurbinectedin in Second-line SCLC

January 26th 2023

Balazs Halmos, MD, discusses the safety and efficacy of lurbinectedin in the second-line setting for patients with small cell lung cancer.

Dr. Halmos on Trastuzumab Deruxtecan in NSCLC

November 14th 2022

Balazs Halmos, MD, discusses the importance of testing for HER2 mutations and exon 20 insertions, which are emerging new targets in non–small cell lung cancer, and how fam-trastuzumab deruxtecan-nxki meets needs for patients with HER2-mutant disease.